Parkinson's disease

Nov 25, 2024

Cell and gene therapies are transforming Parkinson's treatment, bringing new hope to patients who previously had few options. While traditional approaches focus on symptom management, these advanced therapies target the underlying causes of the disease. By introducing healthy cells or repairing faulty genes, resear...

Jul 04, 2023

FDA Approves First Gene Therapy for Severe Hemophilia A BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced that the US Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the tr...

Jun 25, 2020

Regeneron recognizes new combos to boost I-O drug Libtayo's cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance...

Apr 23, 2020

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

Jan 30, 2020

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...

Jan 28, 2020

The drug, sotatercept of Acceleron Pharma, touches the phase 2 mark Acceleron Pharma, a clinical-stage biopharmaceutical company based in Boston, Massachusetts with a primary aim on the development of medicines that regulate the transforming growth factor-beta (TGF-β) superfamily of proteins that play significan...